검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Naltrexone |
Overview Company | Sarah Weiss |
Overview Modality | CGT |
Overview Target | Advanced Melanoma |
Overview Indication | Advanced Melanoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | target MORs such as novel low-efficacy MOR agonists or long-acting formulations, and (3) medications that target post-MOR signaling |
MoA Biomarker | biomarkers, long-term safety profiling, sex-specific responses, and real-world effectiveness studies |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Multicentre, double-blind, randomised, placebo-controlled study on the prophylactic use of naldemedine for opioid-induced nausea and vomiting in patients with cancer (POSEIDON study): a protocol paper.. Opioid-induced nausea and vomiting (OINV) in patients with cancer imposes a substantial clinical burden and may compromise adherence to opioid therapy. Naldemedine, a peripheral μ-opioid rece… |
Clinical Primary efficacy | ORR 6.6% |
Clinical ORR | 6.6% |
Clinical Result source | ClinicalTrials.gov NCT01402492 |
Clinical Data Tier / Score | A · 32 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Naltrexone |
Overview Company | Sarah Weiss |
Overview Modality | CGT |
Overview Target | Advanced Melanoma |
Overview Indication | Advanced Melanoma |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
MoA Mechanism | target MORs such as novel low-efficacy MOR agonists or long-acting formulations, and (3) medications that target post-MOR signaling |
MoA Biomarker | biomarkers, long-term safety profiling, sex-specific responses, and real-world effectiveness studies |
PK/PD Species | Rat |
PK/PD Animal (cat.) | Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rat |
Toxicology Animal (cat.) | Rat |
Toxicology Major finding | Multicentre, double-blind, randomised, placebo-controlled study on the prophylactic use of naldemedine for opioid-induced nausea and vomiting in patients with cancer (POSEIDON study): a protocol paper.. Opioid-induced nausea and vomiting (OINV) in patients with cancer imposes a substantial clinical burden and may compromise adherence to opioid therapy. Naldemedine, a peripheral μ-opioid rece… |
Clinical Primary efficacy | ORR 6.6% |
Clinical ORR | 6.6% |
Clinical Result source | ClinicalTrials.gov NCT01402492 |
Clinical Data Tier / Score | A · 32 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교